Because IPO is a fundraising event
-
-
-
Ok, but then the question is why venture funding isn’t available at that stage.
- 3 more replies
New conversation -
-
-
You need to really deeply internalize that the field is dominated by indefinite optimistic thinking.
-
Biotech VCs have been burned so many times on scientific risk that very few of them believe they can predict the results of trials better than chance.
- 4 more replies
New conversation -
-
-
Costly for whom? Investors or management? haha
-
For the company, in legal fees and disclosure requirements. I don’t know much about that process but I was under the impression it was quite difficult.
- 5 more replies
New conversation -
-
-
Good points from
@WilliamAEden above. Preclinical exits are also at a sky high because of platform potential. Exits at Phase I based on recent orphan designations are also pumping prices higher.Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Maybe half-applicable to IPO's, but I heard from a friend who reviews biotech startups for acquisition that the biggest value is created from founding to safety trials. Many sell to large corps before efficacy trials, to capture most value, without risk of entire thing busting.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Lack of late stage capital for them?
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
Great big pots of money.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.